LINEZOLID. The discovery and clinical development of effective antibiotics is most remarkable achievement over the past 60 years. Since the introduction of the sulphonamides in 1936, researchers have developed a range of antibiotic classes.
The discovery and clinical development of effective antibiotics is most remarkable achievement over the past 60 years.
Until recently, however all new antibiotics introduced over the past 35 years have been structural modifications of existing antibiotic classes.
The oxazolidinones represent the first truly new class of antibacterial agents.
Linezolid is the first of a new class of anti microbial agents, the Oxazolidinones, whose mechanism of action differs from that of existing agents.
Cross resistance to other antimicrobials is therefore less likely and has not been shown till date.
Metabolism: It is primarily metabolized by oxidation of the morphine ring which results in two inactive ring-opened carboxylic acid metabolites
Excretion: Non renal clearance accounts for about 65% of total clearance.
Enterococcus faecalis (including vancomycin-resistan strains)
Enterococcus faecalis (vancomycin-susceptible strains)
Staphylococcus epidermidis (including methicillin- resistant strains)
Streptococcus pneumoniae (penicillin-resistant strains)
Viridans group streptococci
Complicated skin and skin structure infections caused by staphylococcus aureus (methicillin-susceptible and resistant strains), streptococcus pyogenes, or streptococcus agalactiae
CBC, Hb & Platelet count: particularly in patients who are at increased risk for bleeding, patients with pre-existing thrombocytopenia or Myelosuppression or concomitant medications that decrease platelet count or function or produce bone marrow suppression and in patient requiring more than 2 weeks therapy.
LINEZOLID is contraindicated for use in patients who have known hypersensitivity to Linezolid or any of the other product components.
No dose adjustment is recommended in case of mild & moderate hepatic insufficiency.